Selected Grants
CISA 2023 Clinical Contributing Task 1
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2028CISA 2023 Clinical Contributing Task 2
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2028Clinical and host microbiome features in the development of acute otitis media
ResearchAdvisor · Awarded by National Institute of Allergy and Infectious Diseases · 2023 - 2028CIVICS Component C - Option 8B.2 Phase 1
ResearchInvestigator · Awarded by National Institutes of Health · 2026 - 2028CISA 2024 RSV Infants Nirsevimab Study Task 1 - Lead
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2024 - 2027A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healty Infants
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2026 - 2027MK-8228 (letermovir) PK in pediatric kidney transplant recipients
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme LLC · 2025 - 2027A Phase 2, randomized, double-blind trial to evaluate the safety, tolerability, and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy infants
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2024 - 2027Phase 1: A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
ResearchInvestigator · Awarded by Leidos Biomedical Research, Inc. · 2026 - 2026A Phase 1 Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Antigenically Central (AC)-Anhui mRNA-LNP Vaccine in Healthy Adults 25CTA-DM0002
Clinical TrialInvestigator · Awarded by Leidos Biomedical Research, Inc. · 2025 - 2026A Phase 1, randomized, double-blind, sponsor-open study to describe the safety and tolerability of a multivalent Pneumococcal Conjugate Vaccine in adults
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2025 - 2026CIVICs Component C Year 7 - Option 6
ResearchInvestigator · Awarded by National Institutes of Health · 2019 - 2026CIVICS Component C - Option 9
ResearchInvestigator · Awarded by National Institutes of Health · 2020 - 2026A Phase 2, randomized, partially double-blind trail to evaluate the safety, tolerability and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in healthy toddlers 12 through 15 months of age.
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2024 - 2026Lead Site Optional Task 1: Babies COVID-19 Vaccination
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2025Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses - Option 1
ResearchInvestigator · Awarded by National Institutes of Health · 2022 - 2025CIVICS Component C - Option 8
ResearchInvestigator · Awarded by National Institutes of Health · 2020 - 2024CISA COVID Peds Immunogenicity
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2024CISA 10-Pediatric COVID-19 Vaccination (Lead)
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2021 - 2024A Phase 1, Open-Label, Age-Descending, Dose-Finding Study and A Phase 2/3, Placebo-Controlled, Randomized, Double-Blind Study To Evaluate the Safety, Tolerability and Immunogenicity of Respiratory Synctial Virus Perfusion F Subunit Vaccine - RSVpreF
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2023 - 2024Pfizer C4671026
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2022 - 2024Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses - Option 4
ResearchInvestigator · Awarded by National Institutes of Health · 2023 - 2024A Master Protocol to Investigate the Safety, Tolerability and Immunogenicity of Bivalent BNT162b2 RNA-Based Vaccine Candidate(s) in Healthy Infants and Children
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2022 - 2023CISA Consult 2022 Contributing Task 3
Clinical TrialPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2023CISA Consult 2022 Contributing Task 1
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2023Leveraging National Healthcare Safety Network Antimicrobial Use Option to Inform, Implement and Assess Antibiotic Stewardship Activities
ResearchConsultant · Awarded by Centers for Disease Control and Prevention · 2022 - 2023CISA RFTP Syncope Prevention Study (Lead) 2020-2022
ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2020 - 2022Clinical Vaccine Safety Evaluation - Contributing Site - Task COVID - Optional Task 3
ResearchCo Investigator · Awarded by Centers for Disease Control and Prevention · 2020 - 2022FY21 and FY22 Improving Care Quality for Children 50/50
ResearchPrincipal Investigator · Awarded by University of Louisville Research Foundation, Inc. · 2020 - 2022Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Toddlers and Infants
Clinical TrialPrincipal Investigator · Awarded by Sanofi US · 2020 - 2022The impact of a provider feedback intervention on inappropriate antibiotic prescribing in Kentucky children: An interrupted time series analysis
ResearchPrincipal Investigator · Awarded by University of Louisville Research Foundation, Inc. · 2021 - 2022Evaluating SARS-CoV2 vaccine effectiveness among health care personnel during early phase vaccination
ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2020 - 2021VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Option 1
ResearchInvestigator · Awarded by National Institutes of Health · 2020 - 2021Characterizing Health Disparities in the Shift to North Carolina Medicaid Managed Care
ResearchInvestigator · Awarded by Kate B. Reynolds Charitable Trust · 2020 - 2021VTEU Protocol Implementation Option 1
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2019 - 2021A Phase 1, Open-Label, Multicenter Study to Determine the Pharmacokinetics and Safety of Intravenous Eravacycline in Children with Suspected or Confirmed Bacterial Infection
Clinical TrialPrincipal Investigator · Awarded by Tetraphase Pharmaceuticals, Inc. · 2019 - 2021A cross-sectional analysis of inappropriate outpatient antibiotic use in children insured by Kentucky Medicaid
ResearchPrincipal Investigator · Awarded by University of Louisville Research Foundation, Inc. · 2020 - 2021A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus T
Clinical TrialPrincipal Investigator · Awarded by Moderna Therapeutics, Inc. · 2020 - 2020VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Base
ResearchInvestigator · Awarded by National Institutes of Health · 2019 - 2020Improving Care Quality for Children Receiving Kentucky Medicaid
ResearchPrincipal Investigator · Awarded by University of Louisville Research Foundation, Inc. · 2019 - 2020VTEU Task Order 18-0011.B1.C1.0116-Task B Base
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2018 - 2019VTEU RTOP FY.2019.A1B1C1D1.0103 - Task A - Base
ResearchInvestigator · Awarded by National Institutes of Health · 2018 - 2019Improving Care Quality for Children Receiving Kentucky Medicaid
ResearchPrincipal Investigator · Awarded by University of Louisville Research Foundation, Inc. · 2017 - 2019VTEU Task Order 16-0047.C1.0090
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2018 - 2018VTEU Task Order 16-0047 -Task C Option 1
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2018 - 2018External Relationships
- Merck
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.